<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">One of the first vaccine, mRNA-1273, developed by the National Institute of Allergy and Infectious Diseases in association with Moderna, is under phase1/phase 2 of the clinical trial. An mRNA-1273 encoding for S protein of SARS-CoV-2 is encapsulated into lipid nanoparticles and delivered into the cell to generate an immune response against S protein [
 <xref rid="bib138" ref-type="bibr">138</xref>].
</p>
